Long-term PERSEUS results confirm sustained benefit of daratumumab-based therapy in newly diagnosed multiple myeloma
6 Nov 2026
Long-term PERSEUS results confirm sustained benefit of daratumumab-based therapy in newly diagnosed multiple myeloma
Daratumumab and isatuximab show comparable efficacy in newly diagnosed multiple myeloma
Isa-VRd shows sustained benefit in transplant-ineligible newly diagnosed multiple myeloma